Aurora kinase inhibitor patents and agents in clinical testing

An update (2009 - 10)

Chun-Hei Cheung, Mohane Selvaraj Coumar, Jang-Yang Chang, Hsing Pang Hsieh

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Introduction: Mitosis is a key step in the cell cycle and is controlled by several cell cycle regulators, including aurora kinases. Aurora family members A, B and C are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis. Overexpression/amplification of aurora kinases has been implicated in oncogenic transformation, including the development of chromosomal instability in cancer cells. Hence, the use of aurora kinase small molecule inhibitors as a potential molecular-targeted therapeutic intervention for cancer is being pursued by various researchers. Area covered: This review provides an update on aurora kinase inhibitors based on developments from 2009 to 2010. The medicinal chemistry aspects of aurora kinase inhibitors, with a particular emphasis on the patent literature, are reviewed. Databases such as PubMed, SCOPUS, Scifinder and www.clinicaltrials.gov database were used to search for literature in the preparation of this review. Expert opinion: Around a dozen aurora kinase inhibitors are currently undergoing various Phase I - II evaluations for different human cancers. Instead of being applied as a monotherapy, combinations of aurora kinase inhibitors and existing chemotherapeutic compounds seem to give better therapeutic outcomes and are, therefore, a promising future cancer therapy.

Original languageEnglish
Pages (from-to)857-884
Number of pages28
JournalExpert Opinion on Therapeutic Patents
Volume21
Issue number6
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

Aurora Kinases
Patents
Neoplasms
Cell Cycle
Databases
Literature
Centrosome
Chromosomal Instability
Cytokinesis
Pharmaceutical Chemistry
Expert Testimony
Mitosis
PubMed
Therapeutics
Research Personnel

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

@article{d0e355d93eb74cf095b9446f9c917829,
title = "Aurora kinase inhibitor patents and agents in clinical testing: An update (2009 - 10)",
abstract = "Introduction: Mitosis is a key step in the cell cycle and is controlled by several cell cycle regulators, including aurora kinases. Aurora family members A, B and C are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis. Overexpression/amplification of aurora kinases has been implicated in oncogenic transformation, including the development of chromosomal instability in cancer cells. Hence, the use of aurora kinase small molecule inhibitors as a potential molecular-targeted therapeutic intervention for cancer is being pursued by various researchers. Area covered: This review provides an update on aurora kinase inhibitors based on developments from 2009 to 2010. The medicinal chemistry aspects of aurora kinase inhibitors, with a particular emphasis on the patent literature, are reviewed. Databases such as PubMed, SCOPUS, Scifinder and www.clinicaltrials.gov database were used to search for literature in the preparation of this review. Expert opinion: Around a dozen aurora kinase inhibitors are currently undergoing various Phase I - II evaluations for different human cancers. Instead of being applied as a monotherapy, combinations of aurora kinase inhibitors and existing chemotherapeutic compounds seem to give better therapeutic outcomes and are, therefore, a promising future cancer therapy.",
author = "Chun-Hei Cheung and Coumar, {Mohane Selvaraj} and Jang-Yang Chang and Hsieh, {Hsing Pang}",
year = "2011",
month = "6",
day = "1",
doi = "10.1517/13543776.2011.574614",
language = "English",
volume = "21",
pages = "857--884",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "6",

}

Aurora kinase inhibitor patents and agents in clinical testing : An update (2009 - 10). / Cheung, Chun-Hei; Coumar, Mohane Selvaraj; Chang, Jang-Yang; Hsieh, Hsing Pang.

In: Expert Opinion on Therapeutic Patents, Vol. 21, No. 6, 01.06.2011, p. 857-884.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Aurora kinase inhibitor patents and agents in clinical testing

T2 - An update (2009 - 10)

AU - Cheung, Chun-Hei

AU - Coumar, Mohane Selvaraj

AU - Chang, Jang-Yang

AU - Hsieh, Hsing Pang

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Introduction: Mitosis is a key step in the cell cycle and is controlled by several cell cycle regulators, including aurora kinases. Aurora family members A, B and C are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis. Overexpression/amplification of aurora kinases has been implicated in oncogenic transformation, including the development of chromosomal instability in cancer cells. Hence, the use of aurora kinase small molecule inhibitors as a potential molecular-targeted therapeutic intervention for cancer is being pursued by various researchers. Area covered: This review provides an update on aurora kinase inhibitors based on developments from 2009 to 2010. The medicinal chemistry aspects of aurora kinase inhibitors, with a particular emphasis on the patent literature, are reviewed. Databases such as PubMed, SCOPUS, Scifinder and www.clinicaltrials.gov database were used to search for literature in the preparation of this review. Expert opinion: Around a dozen aurora kinase inhibitors are currently undergoing various Phase I - II evaluations for different human cancers. Instead of being applied as a monotherapy, combinations of aurora kinase inhibitors and existing chemotherapeutic compounds seem to give better therapeutic outcomes and are, therefore, a promising future cancer therapy.

AB - Introduction: Mitosis is a key step in the cell cycle and is controlled by several cell cycle regulators, including aurora kinases. Aurora family members A, B and C are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis. Overexpression/amplification of aurora kinases has been implicated in oncogenic transformation, including the development of chromosomal instability in cancer cells. Hence, the use of aurora kinase small molecule inhibitors as a potential molecular-targeted therapeutic intervention for cancer is being pursued by various researchers. Area covered: This review provides an update on aurora kinase inhibitors based on developments from 2009 to 2010. The medicinal chemistry aspects of aurora kinase inhibitors, with a particular emphasis on the patent literature, are reviewed. Databases such as PubMed, SCOPUS, Scifinder and www.clinicaltrials.gov database were used to search for literature in the preparation of this review. Expert opinion: Around a dozen aurora kinase inhibitors are currently undergoing various Phase I - II evaluations for different human cancers. Instead of being applied as a monotherapy, combinations of aurora kinase inhibitors and existing chemotherapeutic compounds seem to give better therapeutic outcomes and are, therefore, a promising future cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=79956223049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956223049&partnerID=8YFLogxK

U2 - 10.1517/13543776.2011.574614

DO - 10.1517/13543776.2011.574614

M3 - Review article

VL - 21

SP - 857

EP - 884

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 6

ER -